Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerBilling CodesAdministrative, Miscellaneous and InvestigationalHCPCS hcpcs-a9576-gadoteridol-prohance-injection-per-ml
    Ask Trek AI about this page

    HCPCS Level II A9576: Injection, gadoteridol (ProHance), per ml

    HCPCS Level II code A9576 describes per‑milliliter billing for the gadoteridol injectable MRI contrast agent (ProHance multipack), used as an intravenous contrast medium for magnetic resonance imaging studies; the service is a radiology contrast administration product typically provided in outpatient imaging centers, hospital radiology departments, or ambulatory care settings to enhance diagnostic MR image quality.

    For related coverage guidance, see recent payer policy updates: Patient-Controlled End Range of Motion Stretching Devices, Sleep Position Trainer, Hospital Beds Corporate Medical Policy.

    Customize your policy alerts

    Sign up for hcpcs A9576 policy alerts

    Get alerted when payer policies referencing A9576 are released or updated.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Table of contents

    Progress1 / 7

    Explore openpayer tools

    • Billing CodesCPT, HCPCS, DRG & more
    • Reimbursement RatesCommercial vs. Medicare rate reports
    • Facility ComparisonBeds, revenue & payer mix
    • ProvidersHospitals & facilities
    • PayersPlans & market footprint
    • Taxonomy CodesNUCC specialty codes
    • ModifiersCPT modifiers & usage
    • Prior AuthorizationPA policies by payer & drug
    • Timely FilingFiling deadlines by payer
    • Coverage CriteriaMedical necessity by payer
    • Payer ContactsClaims, PA & appeals contacts
    View all tools

    Clinical & Coding Specifications

    Clinical Context

    A typical patient is an adult referred for a contrast-enhanced magnetic resonance imaging (MRI) study of the brain, spine, or joints to evaluate for tumor, infection, inflammation, demyelinating disease, or internal derangement. The patient arrives at an outpatient radiology imaging center or hospital radiology department. The clinical workflow includes verification of the exam order and indications, review of renal function (e.g., recent serum creatinine or eGFR), allergy screening, informed consent for intravenous contrast, placement of an IV cannula by a registered nurse or radiology technologist, and preparation of the gadoteridol (ProHance) multipack vial(s). The radiologist or qualified MRI technologist administers the contrast intravenously, typically calculated by weight-based volume in milliliters; the billing code A9576 is reported per milliliter of gadoteridol used. Post-injection monitoring for immediate adverse reaction occurs for several minutes; the patient then undergoes the MRI sequences requiring contrast. Documentation includes indication, informed consent, renal function assessment, volume of A9576 injected (ml), lot number and expiration, site and method of administration, any immediate reactions and management, and the performing provider and their taxonomy. Typical sites of service are outpatient radiology centers, hospital outpatient departments, and inpatient hospital settings for emergent imaging.

    Related CPT Codes

    CPT CodeDescriptionRelationship to This Procedure
    70553Magnetic resonance imaging, brain (with contrast)Frequently performed with A9576 to provide contrast-enhanced brain MRI sequences.
    72156Magnetic resonance imaging, pelvis, without and with contrast, or with contrast only (contrast-enhanced pelvis MRI)Performed when gadoteridol is used for pelvic MRI protocols.
    73721Magnetic resonance imaging, lower extremity joint, with contrastUsed when contrast-enhanced joint imaging is required; gadoteridol billed with A9576.
    72291Magnetic resonance imaging, cervical spine (with contrast)Cervical spine MRI with contrast uses gadoteridol billed per ml with A9576.
    70551Magnetic resonance imaging, brain (without contrast)May be performed before deciding on contrast-enhanced sequences; not directly billed with A9576 but part of workflow.

    Related Modifiers

    7 rows

    ModifierDescriptionWhen to Use
    22Modifier –22 (Increased Procedural Services) is used when a reported procedure is substantially more extensive than normally required. The CPT Manual and CMS state it may be appended only when the…- When to use: Append modifier -22 to a procedural CPT code when the service performed is substantially more extensive than the usual service described by that code — i.e., the procedure required…
    23Modifier -23 (Unusual Anesthesia) is used on anesthesia service CPT codes when a procedure that normally requires no anesthesia or only local anesthesia must be performed under general anesthesia…- Use modifier -23 only on anesthesia CPT codes (00100–01999) when a procedure that normally requires no anesthesia or only local anesthesia must be performed under general anesthesia because of…
    52Modifier ‑52 (Reduced Services) indicates that a service or procedure was partially reduced or omitted at the provider’s discretion, allowing reporting of the basic procedure number with a qualifier…- Use modifier -52 when a physician or qualified health professional electively reduces or omits part of a procedure or service (for example, performing fewer required views or omitting a portion of…
    53Modifier 53 (Discontinued Procedure) signals that a surgical or diagnostic service was begun by the physician but terminated because of extenuating circumstances that threatened the patient’s…- Use modifier -53 when a physician/qualified healthcare professional has started a surgical or diagnostic procedure (e.g., anesthesia administered, incision or scope insertion) and then discontinues…
    62Modifier 62 indicates that two surgeons function as co‑surgeons, each performing distinct parts of the same primary surgical procedure. It is appended to the primary procedure code (and any…- Use modifier -62 when two surgeons act as co‑surgeons (both primary surgeons) on a single definitive primary procedure, each performing distinct parts of the same surgical procedure (append -62 to…
    78CPT modifier -78 indicates an unplanned, related return to the operating or procedure room by the same provider during the global postoperative period. It is appended when treatment for a…- Use modifier -78 when an unplanned, related complication during the original procedure’s global postoperative period requires the patient to return to a formal operating or procedure room and the…
    80CPT® Modifier 80 (Assistant Surgeon) is appended to a surgical CPT code when a physician (MD or DO) provides full, continuous assistance throughout the operative procedure. It is intended only for…- Use CPT Modifier -80 when a physician (MD or DO) serves as an assistant surgeon and provides full, continuous assistance throughout the entire operative procedure; append -80 to the surgical CPT…

    Related Provider Taxonomies

    8 rows

    Taxonomy Code
    225100000X
    363L00000X
    1710I1003X
    324500000X
    2080P0214X
    225400000X
    2083T0002X
    2081P0010X

    Related ICD-10-CM Codes

    26 rows

    ICD-10-CM CodeDescription
    C70.9Malignant neoplasm of meninges, unspecified
    C71.4Malignant neoplasm of occipital lobe
    C71.9Malignant neoplasm of brain, unspecified
    C79.31Secondary malignant neoplasm of brain
    D33.3Benign neoplasm of cranial nerves
    F44.4Conversion disorder with motor symptom or deficit
    G40.909Epilepsy, unspecified, not intractable, without status epilepticus
    G44.1Vascular headache, not elsewhere classified
    G44.209Tension-type headache, unspecified, not intractable
    G45.9Transient cerebral ischemic attack, unspecified

    Showing 1–10 of 26

    Related Payer Policy Updates

    Specialty: Durable Medical Equipment (DME)1 / 3

    10 rows

    PolicyPayerEffective Date
    Patient-Controlled End Range of Motion Stretching DevicesBluecross Idaho2027-01-01
    Sleep Position Trainerregence2027-01-01
    Hospital Beds Corporate Medical Policybcbsvermont2027-01-01
    Continuous Passive Motion Devices with Remote Monitoring or Adaptive CapabilitiesBlue Cross Blue Shield - Rhode Island2026-12-01
    Bone Growth StimulatorsMass General Brigham Health Plan2026-12-01
    Prior Authorization for Durable Medical Equipment (DME)Blue Cross Blue Shield - Rhode Island2026-12-01
    Patient Liftsuniverahealthcare2026-11-16
    Durable Medical Equipment RepairsCareSource Georgia2026-11-01
    Custom Compression GarmentsModa Health2026-11-01
    Tonic Motor Activation (TOMAC) for Restless Legs Syndromeregence2026-11-01

    Related Codes

    HCPCS-A9150-NON-PRESCRIPTION-DRUGS

    HCPCS Level II A9150: Non-prescription Drugs

    HCPCS-A9152-SINGLE-ORAL-VITAMIN-MINERAL-DOSE

    HCPCS A9152: Single Oral Vitamin/Mineral/Trace Element

    HCPCS-A9153-MULTIVITAMIN-ORAL-PER-DOSE

    HCPCS A9153: Multiple Vitamins, Oral, Per Dose

    HCPCS-A9154-ARTIFICIAL-SALIVA-1ML

    HCPCS Level II A9154: Artificial saliva, 1 ml

    HCPCS-A9155-ARTIFICIAL-SALIVA-30ML

    HCPCS Level II A9155: Artificial Saliva, 30 mL

    HCPCS-A9156-ORAL-MUCOADHESIVE-PER-1ML

    HCPCS Level II A9156: Oral Mucoadhesive, Per 1 ml

    HCPCS-A9180-PEDICULOSIS-TOPICAL-TREATMENT-PATIENT-ADMINISTRATION

    HCPCS Level II A9180: Pediculosis Topical Treatment for Patient/Caretaker

    HCPCS-A9268-PROGRAMMER-TRANSIENT-INGESTED-CAPSULE

    HCPCS Level II A9268: Programmer for Transient Orally Ingested Capsule

    HCPCS-A9269-PROGRAMMABLE-TRANSIENT-ORAL-CAPSULE

    HCPCS Level II A9269: Programmable Orally Ingested Capsule, Per Month

    HCPCS-A9270-NON-COVERED-ITEM-OR-SERVICE

    HCPCS A9270: Non-covered Item or Service

    Showing 1–10 of 138

    • More pages

    Frequently Asked Questions

    References

    1. 1.CPT® Codes and Descriptions. AAPC. Retrieved Aug 11, 2026.Maintains the CPT code set's official descriptions and guidelines, licensed from the American Medical Association, used as the definitional source for CPT codes on this page.
    2. 2.HCPCS Quarterly Update. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's quarterly release of HCPCS Level II codes and short/long descriptors, the source for HCPCS code definitions and update history.
    3. 3.ICD-10-CM Full Code List. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's complete ICD-10-CM diagnosis code list, used to cross-reference diagnosis codes associated with this procedure or service.
    Published by

    Trek Health powers OpenPayer with a leading commercial payer intelligence platform, seamlessly converting fragmented payer data into actionable insights for provider organizations.

    Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.